• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.T 细胞复杂性和密度与直肠癌患者对新辅助放化疗的敏感性相关。
Cancer Immunol Immunother. 2021 Feb;70(2):509-518. doi: 10.1007/s00262-020-02705-6. Epub 2020 Aug 26.
2
Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.与直肠癌患者新辅助放化疗反应相关的免疫基因组特征。
Br J Surg. 2019 Sep;106(10):1381-1392. doi: 10.1002/bjs.11179. Epub 2019 Jun 13.
3
Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.肿瘤浸润性PD-1+免疫细胞密度与直肠癌新辅助放化疗反应相关。
Clin Colorectal Cancer. 2022 Mar;21(1):e1-e11. doi: 10.1016/j.clcc.2022.01.004. Epub 2022 Jan 11.
4
Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.全身性炎症标志物联合肿瘤浸润淋巴细胞密度预测直肠癌新辅助放化疗反应的价值。
Ann Surg Oncol. 2021 Oct;28(11):6189-6198. doi: 10.1245/s10434-021-09975-z. Epub 2021 Apr 19.
5
CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.直肠癌放化疗前后CD8 +和FOXP3 +肿瘤浸润性T细胞
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21. doi: 10.1245/s10434-014-3584-y. Epub 2014 Feb 25.
6
Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.术前活检中的肿瘤内芽生和 CD8 阳性 T 细胞密度可预测晚期直肠癌新辅助放化疗的反应。
Clin Colorectal Cancer. 2023 Dec;22(4):411-420.e1. doi: 10.1016/j.clcc.2023.07.004. Epub 2023 Jul 22.
7
Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.直肠癌放化疗开始后 7 天获得的活检标本中的肿瘤浸润淋巴细胞是预测放化疗反应的标志物。
Oncology. 2020;98(12):869-875. doi: 10.1159/000508922. Epub 2020 Aug 14.
8
Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer.活检样本中 CD4(+)和 CD8(+)T 淋巴细胞的密度可预测直肠癌放化疗的病理反应。
Radiat Oncol. 2011 May 16;6:49. doi: 10.1186/1748-717X-6-49.
9
A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8 cells in locally advanced rectal cancer.一种预测局部晚期直肠癌中肿瘤浸润 CD8 细胞经放化疗诱导改变的放射组学特征模型。
Radiother Oncol. 2021 Sep;162:124-131. doi: 10.1016/j.radonc.2021.07.004. Epub 2021 Jul 12.
10
Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.直肠癌新辅助放化疗前肿瘤浸润调节性T细胞密度不能预测治疗反应。
Oncotarget. 2017 Mar 21;8(12):19803-19813. doi: 10.18632/oncotarget.15048.

引用本文的文献

1
Peripheral Blood T-Cell Receptor Repertoire Diversity as a Potential Biomarker in the Diagnosis and Treatment Evaluation of Colorectal and Lung Cancers: A Prospective Observational Study.外周血T细胞受体谱多样性作为结直肠癌和肺癌诊断及治疗评估的潜在生物标志物:一项前瞻性观察研究
Cancer Med. 2025 May;14(10):e70937. doi: 10.1002/cam4.70937.
2
The Current Status of T Cell Receptor (TCR) Repertoire Analysis in Colorectal Cancer.T细胞受体(TCR)库分析在结直肠癌中的现状
Int J Mol Sci. 2025 Mar 17;26(6):2698. doi: 10.3390/ijms26062698.
3
Human TCR repertoire in cancer.人类 TCR 库在癌症中的作用。
Cancer Med. 2024 Sep;13(17):e70164. doi: 10.1002/cam4.70164.
4
Exploring the potential of the TCR repertoire as a tumor biomarker (Review).探索T细胞受体库作为肿瘤生物标志物的潜力(综述)。
Oncol Lett. 2024 Jun 28;28(3):413. doi: 10.3892/ol.2024.14546. eCollection 2024 Sep.
5
Research advances on TIL therapy for colorectal cancer.结直肠癌 TIL 疗法的研究进展。
Clin Transl Oncol. 2024 Dec;26(12):2917-2923. doi: 10.1007/s12094-024-03530-4. Epub 2024 May 28.
6
Poor clinical outcomes and immunoevasive contexture in CD161CD8 T cells barren human pancreatic cancer.CD161CD8 T 细胞耗竭的人类胰腺癌临床结局不良且免疫逃避。
J Immunother Cancer. 2024 Mar 26;12(3):e008694. doi: 10.1136/jitc-2023-008694.
7
Modulation of CD8 T Cell Responses by Radiotherapy-Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors.放疗调控 CD8 T 细胞反应:联合免疫检查点抑制剂的当前证据和原理。
Int J Mol Sci. 2023 Nov 24;24(23):16691. doi: 10.3390/ijms242316691.
8
Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.局部晚期直肠癌的新辅助治疗和 PD-1/PD-L1 检查点抑制剂。
Front Immunol. 2023 Mar 24;14:1149122. doi: 10.3389/fimmu.2023.1149122. eCollection 2023.
9
Characterization of the gene signature correlated with favorable response to chemoradiotherapy in rectal cancer: A hypothesis-generating study.直肠癌化放疗疗效相关基因特征的鉴定:一项假说生成研究。
Cancer Med. 2023 Apr;12(7):8981-8990. doi: 10.1002/cam4.5586. Epub 2023 Jan 9.
10
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?浸润肿瘤的淋巴细胞治疗实体瘤:需要双人探戈?
Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022.

本文引用的文献

1
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.p53免疫组化染色可预测高危直肠癌患者放化疗后的残留病灶。
Clin Cancer Res. 1997 Oct;3(10):1685-90.

T 细胞复杂性和密度与直肠癌患者对新辅助放化疗的敏感性相关。

T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.

机构信息

Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

出版信息

Cancer Immunol Immunother. 2021 Feb;70(2):509-518. doi: 10.1007/s00262-020-02705-6. Epub 2020 Aug 26.

DOI:10.1007/s00262-020-02705-6
PMID:32845355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10991251/
Abstract

Emerging evidence suggests that an increased density of pre-treatment CD8 tumor-infiltrating lymphocytes (TILs) is associated with good response to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. However, the significance of T-cell complexity in the clinical setting remains unknown. High-throughput T-cell receptor (TCR) β sequencing was applied to quantify the TCR repertoire of pre-treatment biopsies from 67 patients with advanced rectal cancer receiving preoperative CRT. Diversity index was used to represent the complexity of the TCR repertoire in a tumor. Pre-treatment CD8 TIL densities were assessed by immunohistochemistry. Changes in TCR repertoire before and after CRT were also analysed in 23 patients. Diversity indices were significantly higher for good responders than for non-responders (P = 0.031). The multivariate analysis revealed that both CD8 TIL density and TCR diversity index were independently associated with good response to CRT (P < 0.001 and P = 0.049, respectively). Patients who were high for both CD8 TIL density and TCR diversity (double-high) had markedly better responses to CRT than double-low patients (84.2% vs 16.7%, P < 0.0001). Larger changes in TCR repertoires before and after CRT were correlated with better recurrence-free survival (P = 0.027). The complexity and dynamic change in the TCR repertoire might serve as a useful indicator of response to CRT in combination with CD8 TIL density in patients with rectal cancer.

摘要

越来越多的证据表明,治疗前 CD8 肿瘤浸润淋巴细胞(TIL)密度增加与局部晚期直肠癌患者接受放化疗(CRT)的良好反应相关。然而,T 细胞复杂性在临床环境中的意义仍不清楚。高通量 T 细胞受体(TCR)β测序被应用于定量分析 67 例接受术前 CRT 的晚期直肠癌患者治疗前活检标本的 TCR 库。多样性指数用于表示肿瘤中 TCR 库的复杂性。通过免疫组织化学评估治疗前 CD8 TIL 密度。还分析了 23 例患者 CRT 前后 TCR 库的变化。良好反应者的多样性指数明显高于无反应者(P=0.031)。多变量分析显示,CD8 TIL 密度和 TCR 多样性指数均与 CRT 的良好反应独立相关(P<0.001 和 P=0.049)。CD8 TIL 密度和 TCR 多样性均较高的患者(双高)对 CRT 的反应明显优于双低患者(84.2%对 16.7%,P<0.0001)。CRT 前后 TCR 库较大的变化与无复发生存率的改善相关(P=0.027)。TCR 库的复杂性和动态变化可能与 CD8 TIL 密度一起成为直肠癌患者对 CRT 反应的有用指标。